Background reactivation of hepatitis B virus (hBV) replication is a well-recognised complication in patients receiving disease-modifying anti-rheumatic drugs (DMarDs) for rheumatoid arthritis (ra). limited data exist on hBV reactivation among patients with ra treated with janus kinase (JaK) inhibitors. The objective of the current study was to assess hBV reactivation in clinical trials of baricitinib, an oral selective JaK1 and JaK2 inhibitor in ra. Methods Data were integrated from four completed Phase 3 trials and one ongoing long-term extension (data up to 1 april 2017) in patients naïve to DMarDs or who had inadequate response (ir) to DMarDs including methotrexate (MTX)-ir and/or other conventional synthetic DMarD (csDMarD)-ir, or tumour necrosis factor inhibitors-ir. Within the clinical programme, baricitinib-treated patients may have received concomitant csDMarDs including MTX, or previous treatment with active comparators including MTX or adalimumab + MTX. at screening, all patients were tested for hBV surface antigen (hBsag), core antibody (hBcab) and surface antibody (hBsab). Patients were excluded if they had (1) hBsag+, (2) hBcab+/hBsab− (in Japan, could enrol if hBV Dna−) or (3) hBsab+ and hBV Dna+. hBV Dna monitoring, following randomisation in the originating Phase 3 studies, was performed in Japan for patients with hBcab+ and/or hBsab+ at screening, and was later instituted globally for hBcab+ patients in accordance with evolving guidance for hBV monitoring and management with immunomodulatory therapy. Results in total, 2890 patients received at least one dose of baricitinib in Phase 3 (6993 patient-years exposure). Of 215 patients with baseline serology suggestive of prior hBV infection (hbcab+) who received a post-baseline Dna test, 32 (14.9%) were hBV Dna+ at some point following treatment initiation; 8 of 215 patients (3.7%) had a single quantifiable result (≥29 iU/ml). Of these eight patients, four met the definition of reactivation of hBV (hBV Dna level ≥100 iU/ml); baricitinib was permanently discontinued in four patients, and temporarily interrupted in two patients. no patient developed clinical evidence of hepatitis and in five of eight patients, antiviral therapy was not used. Conclusion hBV reactivation can occur among ra patients treated with DMarDs, including baricitinib, with prior hBV exposure. Our data suggest that such patients should be monitored for hBV Dna during treatment and might be treated safely with the use of antiviral therapy as needed. The risk of hBV reactivation in patients with hBsag treated with baricitinib is unknown.
InTRoduCTIon
Hepatitis B virus (HBV) infection is one of the most serious and prevalent global health problems, affecting more than 2 billion people worldwide. 1 High-HBV prevalence is common in much of the Asia Pacific region, where it is usually acquired
Key messages
What is already known about this subject? ► in patients with occult hepatitis B, hepatitis B virus (hBV) infection may be reactivated. an identified risk factor for hBV reactivation is type and degree of immunosuppression. ► reactivation of hBV replication is a recognised complication in patients receiving biological agents, for conditions such as rheumatoid arthritis (ra); limited data exist on hBV reactivation among patients with ra treated with biological and/or non-biological disease-modifying anti-rheumatic drugs (DMarDs), in particular those receiving janus kinase (JaK) inhibitors.
What does this study add?
► The current study assessed hBV reactivation in clinical trials of baricitinib, an oral selective JaK1 and JaK2 inhibitor in ra. ► in ra patients treated in baricitinib clinical trials who had serology suggestive of prior infection, reactivation was transient and did not account for any clinically relevant adverse events.
How might this impact on clinical practice?
► Our data suggest that patients with prior hBV exposure should be monitored, in accordance with clinical guidelines, for hBV Dna during treatment with DMarDs, including baricitinib, and might be treated safely with the use of antiviral therapy as needed.
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perinatally, and represents three-quarters of chronic HBV-positive subjects globally. [2] [3] [4] In particular, the Western Pacific region (defined by the WHO as 37 countries including China, Japan, South Korea, the Philippines and Vietnam) accounts for nearly half of all chronic HBV infection globally. In Western Europe and North America, HBV infection usually presents as acute hepatitis during adolescence and adulthood. The prevalence has increased owing to population movement and migration from high-prevalence to low-prevalence countries in Europe. 5 6 In acute resolving HBV infection, an adaptive immune response ultimately leads to viral clearance from infected hepatocytes and the development of neutralising antibodies that prevent viral spread. Persons who become HBV surface antigen-negative (HBsAg−) are considered to have resolved hepatitis B. Occult HBV infection is defined by detectable HBV DNA in serum and/or liver in patients who have tested negative for serum HBsAg. 3 Most occult HBV infection patients have low HBV DNA levels in the serum (and liver tissues are generally not easily assessable). These low levels of HBV DNA, as well as their fluctuations, make the detection of this condition difficult. In patients with occult hepatitis B, HBV infection may be reactivated, and the key risk factors for reactivation can be broadly classified into host factors, virologic factors and type and degree of immunosuppression. 7 Since curative therapy for HBV is not currently available, there is a large population at risk for HBV reactivation.
There are two components of reactivation of chronic HBV infection: reactivation of HBV replication, and subsequent flare (or exacerbation) of hepatitis. Reactivation of HBV replication is defined as a marked increase in HBV replication (≥2 log increase from baseline levels or new appearance of HBV DNA to a level of ≥100 IU/ mL) in a person with previously stable or undetectable levels, respectively. 3 Reactivation of HBV replication is a recognised complication in patients receiving biologic agents for conditions such as rheumatoid arthritis (RA), 8 9 and can be transient and clinically silent but is sometimes severe and results in acute hepatic failure. 9 10 However, data regarding the prevalence of occult infection and the incidence of its reactivation in patients with RA under treatment with biological and/or non-biological diseasemodifying anti-rheumatic drugs (DMARDs) are limited, in particular among patients with RA treated with janus kinase (JAK) inhibitors. To date, JAK inhibitors have been associated with the reactivation of varicella zoster virus and, more rarely, cytomegalovirus; however, their impact on HBV is unknown. 11 Baricitinib is an oral selective JAK1 and JAK2 inhibitor approved for the treatment of moderately-to-severely active RA in adults. The objective of the current study was to assess HBV reactivation in clinical trials of baricitinib in RA.
MaTeRIals and MeTHods study population
Data were collected from patients with RA who received at least one dose of baricitinib in Phase 3 originating studies: RA-BEGIN (52-week study of baricitinib 4 mg, as monotherapy or combined with methotrexate (MTX), compared with MTX monotherapy in patients with active RA who had received no or minimal conventional DMARDs); 12 RA-BEAM (52-week study of baricitinib 4 mg compared with adalimumab (ADA) 40 mg and placebo (switched to baricitinib after 24 weeks) in patients with active RA with an inadequate response to MTX; patients on background MTX); 13 RA-BUILD (24- week study of baricitinib 2 mg or 4 mg compared with placebo in patients with RA and an inadequate response to conventional synthetic DMARDs; patients on background conventionalsynthetic DMARDs (csDMARDs)); 14 RA-BEACON (24-week study of baricitinib 2 mg or 4 mg compared with placebo in patients with RA and an inadequate response to tumour necrosis factor inhibitors (TNFi), or other biological DMARDs; patients on background csDMARDs) 15 and an ongoing long-term extension study, RA-BEYOND (NCT01885078) (treatment with baricitinib 2 mg or 4 mg) up to 1 April 2017. This analysis included patients treated with baricitinib 2 mg or 4 mg concomitantly with ≥1 csDMARD including MTX, baricitinib 4 mg monotherapy, baricitinib 4 mg + MTX, ADA + MTX or MTX alone. Notably, because the studies included an option for rescue and protocol-mandated treatment switching, patients receiving baricitinib 4 mg may have previously received ADA + MTX or MTX alone.
At screening, all patients were tested for HBsAg, core antibody (HBcAb) and surface antibody (HBsAb). In Japan and elsewhere, if required by local clinical guidelines, patients had screening HBV DNA tests. Patients were excluded from treatment in these studies if they had (1) HBsAg+, (2) HBsAb−/HBcAb+ (although in Japan, patients could enrol if HBV DNA−) or (3) HBsAb+ and HBV DNA+. In all studies, concomitant stable doses of csDMARDs, non-steroidal anti-inflammatory drugs, analgesics or glucocorticoids (≤10 mg of prednisone or the equivalent per day) were permitted.
HBV dna monitoring and evaluation of HBV reactivation
Per-protocol, routine monthly HBV DNA monitoring following treatment initiation (post-baseline) was performed in Japan for patients with HBcAb+ and/or HBsAb+ at screening. Monitoring approximately every 3 to 6 months was instituted globally (with the exception of Japan, where monthly monitoring had already been established) for patients with HBcAb+ at baseline, in accordance with evolving guidance for HBV monitoring and management with immunomodulatory therapy. 3 As the guidance changed during study conduct, protocol addenda were implemented in RA-BEGIN, RA-BEAM and RA-BEYOND to retrospectively test patients with HBcAb+ at baseline; addenda were not implemented for the already completed RA-BUILD and RA-BEACON studies. Patients with post-baseline HBV DNA ≥29 IU/mL met study drug discontinuation criteria, and were referred to a hepatologist. In select cases, investigators continued study drug following an HBV DNA+ test ≥29 IU/mL in consultation with the sponsor and in accordance with HBV management guidelines. Monthly monitoring and consultation with a hepatologist were recommended for all patients with two or more results with a value of <29 IU/mL. Per investigator decision, post-baseline HBV DNA testing with or without concomitant hepatic monitoring (alanine transaminase (ALT)/aspartate transaminase (AST) evaluation) was done for patients who were HBcAb− at baseline. Reactivation of HBV replication is defined as a marked increase in HBV replication (≥2 log increase from baseline levels or new appearance of HBV DNA to a level of ≥100 IU/mL) in a person with previously stable or undetectable levels, respectively. 3
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laboratory (HBV dna monitoring)
The lower limit of quantification (LLQ) was 29 IU/mL; the lower limit of detection was 2.4 IU/mL (1 IU/mL HBV is equivalent to 5.6 copies/mL). 16 statistical analyses Data were integrated from four completed Phase 3 trials and one ongoing long-term extension (LTE) (data up to 1 April 2017; median exposure=998 days, maximum exposure=1583 days) (all baricitinib RA Phase 3 analysis set: studies RA-BEGIN (JADZ), RA-BEAM (JADV), RA-BUILD (JADX), RA-BEACON (JADW) and RA-BE-YOND (JADY; LTE)). Baseline demographic information and clinical characteristics were analysed using descriptive statistics. HBV DNA testing at baseline was not systematically performed across the Phase 3 studies; however, testing was performed to inform study entry criteria for patients who were HBsAb+/HBcAb+ (n=255) or HBsAb−/HbcAb+ (n=14) (figure 1). In the HBsAb−/HbcAb+ cohort (n=14), eight patients were from Japan and had HBV DNA− tests at baseline (met study inclusion criteria) and six patients entered the studies from regions other than Japan (these cases were reported as protocol violations). with HBsAb+/HBcAb+ serology at baseline did not have post-baseline HBV DNA test results, for reasons which include timing associated with implementation of the protocol addenda. Of the 290 patients who underwent post-baseline testing (including patients in the HBcAb− groups without a baseline HBV DNA result), 36 (12%) had detectable (n=27, <29 IU/mL; or n=9, ≥29 IU/mL) HBV DNA; these patients were from China (11), Japan (9), Taiwan (6), Israel (2), Greece (2), Russia (2), USA (2), Argentina (1) and South Korea (1) (table 2).
ResulTs
Post-baseline HBV dna testing
Patients with hBcab+ at baseline
Thirty-two patients with HBcAb+ serostatus at baseline had detectable HBV DNA (<29 IU/mL or ≥29 IU/mL) at some point following treatment initiation ( figure 1 respectively. The third patient (HBsAb−/HBcAb− at baseline) had three consecutive HBV DNA detectable results <29 IU/mL with no results thereafter; no hepatic enzyme elevations or relevant AEs were reported. No change was made to baricitinib administration and no antiviral treatment was administered. The patient later discontinued from the study and study drug owing to lack of efficacy. Finally, the fourth patient (HBsAb+/HBcAb− at baseline) had a single detectable HBV DNA result <29 IU/ mL, with no hepatic enzyme elevations or relevant AEs reported. This patient did not receive antiviral treatment and continued baricitinib.
dIsCussIon
In a subset of patients with RA from the baricitinib Phase 3 clinical programme with baseline serology suggestive of prior HBV infection (HBcAb+), and HBV DNA results following treatment initiation, HBV reactivation was evaluated. The data suggest that patients with prior HBV infection but without clinical indications of active infection can be treated with DMARDs, including baricitinib, with monitoring for potential reactivation as would be appropriate per current guidelines in a clinical trial setting. Additional data will be needed to fully characterise the potential risk for reactivation of HBV in the context of JAK inhibitors administered in an RA population; however, the current study provides unique and important evidence toward an evaluation of this risk outside of current standard of care and with a once-daily oral JAK inhibitor. In the current study, among patients with RA who had baseline serology suggestive of prior HBV infection, 32 baricitinib-treated patients tested HBV DNA+ (32/215 patients; 14.9%) at some point following treatment initiation up to the study data cut-off date; of these, 3.7% (8/215 patients) had quantifiable results (≥29 IU/mL). Each of the eight patients had only a single quantifiable HBV DNA result; retest results available as of the data cut-off for seven of the eight patients were either detectable, but not quantifiable (<29 IU/mL) (n=3) or not detected (n=4). Four of the eight patients met the definition of reactivation of HBV owing to having an HBV DNA level ≥100 IU/mL. 3 No patient developed clinical evidence of hepatitis and in most cases (five/eight patients) antiviral therapy was not used.
With the introduction of targeted disease-modifying agents with differing mechanisms of action in RA treatment, it is becoming more important to understand the mechanisms whereby treatment with certain agents makes patients more predisposed to HBV reactivation. Among patients with occult HBV infection who are HBsAg-and HBcAb+, assessment of immunosuppressive therapies has shown that the greatest risk of HBV reactivation (≥10%), potentially leading to increased risk of HBV-reactivation related liver failure and liver related mortality, was observed with B-cell depleting therapies such as rituximab and ofatumumab. 7 Similar findings are described in a review published by the American Gastroenterological
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Association Institute, which reported that among chemotherapeutic agents and immunosuppressants, rituximab has the highest risk of HBV reactivation in both HBsAg+ patients and patients with resolved hepatitis B, often associated with acute liver injury, whereas TNFis are classified as moderate-risk for HBV reactivation (1% to 10%) in HBsAg+ carriers. 17 In recent years, increasing attention has been paid to the possibility of HBV reactivation in patients with RA undergoing treatment with biological DMARDs (bDMARDs), and HBV screening is recommended before initiating biologics. 18 Among the available bDMARDs approved for RA, the risk of HBV reactivation under TNFi has been well-described in several observational studies, 1 and the findings of our analyses are comparable to several previous investigations in which occurrence of HBV reactivation in patients with serological markers of past HBV infection was low (0% to 5.3%). [19] [20] [21] [22] In addition, in the majority of patients who tested HBV DNA+ at some point following treatment, HBV DNA became undetectable again within several months, and clinical outcomes were satisfactory.
Observational data for newer bDMARDs with different targets, including those that target the IL-6 (interleukin 6) receptor, are still lacking, with only a few reports published. 1 Consequently, the existing practical guidelines for the prevention and management of viral reactivation are mostly targeted to the older rather than to the newer bDMARDs. JAK inhibition may counteract the suppressive effects of interferon α on viral replication; however, data on the effects of JAK inhibitors on HBV reactivation are limited. A recent retrospective analysis of 116 Taiwanese patients with RA treated with tofacitinib evaluated the risk of HBV reactivation over a 2-year period. 23 Overall, 81 (69.8%) patients had a past HBV infection, based on patients being HBcAb+ with or without HBsAb. Six patients with HBsAg+ and normal ALT levels were defined as HBV carriers (patients with HBsAg+ were excluded from our analyses); in the other 75 patients, HBV infection was considered resolved (defined as prior HBV infection with normal ALT levels, but without detectable serum HBV DNA or HBsAg). Among the six carriers, only two received antiviral prophylaxis during treatment with tofacitinib. Of the four carriers without antiviral prophylaxis, two experienced HBV reactivation during treatment with tofacitinib. No HBV reactivation was observed in patients with resolved infection (using a 10-fold rise in HBV DNA to define HBV reactivation). 24 There is much geographical diversity in the prevalence of HBV, which is highly endemic in Asia and other parts of the world outside North America and Western Europe, findings that are further supported by the results of this study. The frequency of resolved HBV infection in patients with rheumatic disease seems to be directly associated with the general prevalence of HBV infection within respective countries. In a recent literature review, the prevalence of resolved HBV infection in rheumatic disease was found to range from 7.3% to 66% across a number of studies. 25 Rates in Western Europe (7.3% to 26.3%) were generally lower than those observed in Asian countries. HBV prevalence was similar in Japan (up to 31.5%) and South Korea (33.1%), but markedly higher in China (up to 51%) and Taiwan (66.0%).
Our study had a number of limitations. Because this analysis was retrospective, measurement of HBV DNA was not conducted according to a single protocol. Given the evolving guidance for HBV monitoring and management, HBV DNA tests were not routinely performed for all patients, possibly resulting in selection bias. In addition, risk of HBV reactivation in patients with HBsAg treated with baricitinib is unknown, as patients were excluded from the studies if they were positive for HBsAg. Further, results were descriptive, thus limiting the ability to make objective conclusions about the clinical management of patients with evidence of prior HBV infection currently being treated or who may be treated with baricitinib.
Though HBV reactivation was seen in patients with RA treated with DMARDs, including baricitinib, who had serology suggestive of prior infection, reactivation was transient even with continued baricitinib treatment and did not account for any clinically relevant AEs. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting baricitinib treatment. In patients with serology suggestive of prior infection, the level of expression of HBV DNA should be determined. If HBV DNA is detected, a liver specialist should be consulted. Contributors all authors were involved in the study design, and analysis and interpretation of data and/or critically revising the manuscript. all authors agreed to be responsible for all aspects of the work and read and approved the final manuscript to be published.
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